Mindblown: a blog about philosophy.
Earnings call: Li-Cycle pauses construction at Rochester Hub amid escalating costs
Li-Cycle Holdings Corp. announced a halt in construction at the Rochester Hub during its Third Quarter 2023 Earnings Call, citing rising construction costs and financing delays. The company is now estimating the project’s total cost to range between $850 million and $1 billion, a significant leap from the previously disclosed budget of $560 million. Consequently, […]
Earnings call: Lufax reports Q3 2023 earnings, focuses on diversification and consumer finance growth
Lufax Holding Limited (NYSE: LU) reported a mixed third-quarter performance for 2023, with a focus on derisking and diversification for long-term growth. The company revealed a 15.3% increase in new loan sales volume in its consumer finance business, despite a decrease in its total income and outstanding loan balance. Lufax also announced plans to acquire […]
Earnings call: iCAD reports Q3 2023 results, divests Xoft subsidiary, and focuses on ProFound AI Breast Health business
iCAD (NASDAQ:ICAD), Inc. reported a decline in product revenue during the third quarter of 2023, though an increase in gross profit margin and a decrease in operating expenses pointed to an improved financial position. The company also announced the completion of its therapy subsidiary Xoft’s acquisition by Elekta for $5.5 million, marking the end of […]
Earnings call: Lufax reports Q3 2023 earnings, focuses on diversification and consumer finance growth
Lufax Holding Limited (NYSE: LU) reported a mixed third-quarter performance for 2023, with a focus on derisking and diversification for long-term growth. The company revealed a 15.3% increase in new loan sales volume in its consumer finance business, despite a decrease in its total income and outstanding loan balance. Lufax also announced plans to acquire […]
Earnings call: iCAD reports Q3 2023 results, divests Xoft subsidiary, and focuses on ProFound AI Breast Health business
iCAD (NASDAQ:ICAD), Inc. reported a decline in product revenue during the third quarter of 2023, though an increase in gross profit margin and a decrease in operating expenses pointed to an improved financial position. The company also announced the completion of its therapy subsidiary Xoft’s acquisition by Elekta for $5.5 million, marking the end of […]
Earnings call: Lufax reports Q3 2023 earnings, focuses on diversification and consumer finance growth
Lufax Holding Limited (NYSE: LU) reported a mixed third-quarter performance for 2023, with a focus on derisking and diversification for long-term growth. The company revealed a 15.3% increase in new loan sales volume in its consumer finance business, despite a decrease in its total income and outstanding loan balance. Lufax also announced plans to acquire […]
Earnings call: Gevo Inc. Q3 2023: Strong Liquidity Position, Expansion in Renewable Energy, and Awaited IRS Ruling
In the Q3 2023 earnings call, Gevo (NASDAQ:GEVO) Inc., a renewable chemicals and advanced biofuels company, reported a strong liquidity position of $401.3 million, combined revenue and interest income of $9.8 million, and significant progress in its renewable energy projects. The company is currently waiting for an IRS ruling on carbon reductions that will impact […]
Earnings call: Gevo Inc. Q3 2023: Strong Liquidity Position, Expansion in Renewable Energy, and Awaited IRS Ruling
In the Q3 2023 earnings call, Gevo (NASDAQ:GEVO) Inc., a renewable chemicals and advanced biofuels company, reported a strong liquidity position of $401.3 million, combined revenue and interest income of $9.8 million, and significant progress in its renewable energy projects. The company is currently waiting for an IRS ruling on carbon reductions that will impact […]
Earnings call: Clearside Biomedical reports Q3 2023 results, updates on clinical trials and partnerships
Clearside Biomedical (NASDAQ:CLSD), in its Q3 2023 financial results and corporate update call, announced several achievements including the completion of enrollment in its Phase 2b wet age-related macular degeneration (AMD (NASDAQ:AMD)) clinical trial, ODYSSEY. The company also disclosed a partnership with BioCryst (NASDAQ:BCRX) Pharmaceuticals and provided updates on other collaborations. Clearside’s cash and cash equivalents […]
Earnings call: Clearside Biomedical reports Q3 2023 results, updates on clinical trials and partnerships
Clearside Biomedical (NASDAQ:CLSD), in its Q3 2023 financial results and corporate update call, announced several achievements including the completion of enrollment in its Phase 2b wet age-related macular degeneration (AMD (NASDAQ:AMD)) clinical trial, ODYSSEY. The company also disclosed a partnership with BioCryst (NASDAQ:BCRX) Pharmaceuticals and provided updates on other collaborations. Clearside’s cash and cash equivalents […]
Got any book recommendations?